Treatments & Techniques

The Milton S. Hershey Medical Center Skull Base Surgery Team: Comprehensive Care Close to Home

Treatment of skull base tumors, including those affecting the pituitary gland, traditionally entailed opening the skull or making large incisions in the face and removing parts of the facial bones. These invasive procedures caused significant pain and scarring and required long hospital stays.

Penn State Health Tests Novel, Nonsurgical Therapy for Common Form of Bladder Cancer

Patients with a noninvasive, low-grade form of bladder cancer often need multiple surgeries to treat recurrences, which are common. A new chemoablative gel currently under study at Penn State Health may eliminate the need for those procedures.

Advanced Neuromodulation Therapy Provides Relief from Chronic Pain for Local Patients

Specialty-trained surgeons at Penn State Health Milton S. Hershey Medical Center offer the most up-to-date neuromodulation therapy, dorsal root ganglion (DRG) stimulation, to address chronic neuropathic pain that is resistant to other treatment methods.

Illuminating a Path to Enhanced Bladder Cancer Detection

With its acquisition of Blue Light Cystoscopy with Cysview in December 2018, the urological team at Penn State Health Milton S. Hershey Medical Center is able to look into the bladder with pinpoint accuracy and immediately remove cancerous lesions that are invisible to the naked eye. More thorough eradication of tumors may reduce recurrence rates and the likelihood that missed cells will develop into more aggressive malignancies.

Penn State Health Milton S. Hershey Medical Center Provides Comprehensive Kidney and Liver Transplant Care

The Milton S. Hershey Medical Center’s abdominal transplant program provides comprehensive care for central Pennsylvania residents through kidney and liver transplantation and offers deceased and living donor transplantation for both kidney and liver patients. Hershey Medical Center also has the region’s only adult live donor liver transplant and pediatric kidney transplant programs. Expertise in transplantation is available for medical professionals and their patients close to home, without the need to travel to major cities.

Penn State Heart and Vascular Institute: Advanced, Comprehensive Care Close to Home

By marshaling a collaborative team of specialists and subspecialists at two locations in central Pennsylvania, Penn State Heart and Vascular Institute enables patients with even the most complex cardiovascular conditions to receive innovative, high-level care locally.

Hershey Medical Center Achieves More Accurate Prostate Cancer Diagnosis with MRI-Guided Fusion Biopsy

Merging the capabilities of MRI and ultrasound technology in real time, Penn State Health Milton S. Hershey Medical Center uses MRI-guided fusion biopsy to more accurately detect the presence and aggressiveness of prostate cancer. This innovative technique facilitates accurate prostate cancer diagnosis while reducing the possibility of nondiagnostic biopsies and the need for repeat procedures.

Leveraging 3D Printing for Less Invasive, More Effective Reconstructive Surgery

3D-printed models and implants have revolutionized craniofacial and other reconstructive surgeries at Penn State Health Milton S. Hershey Medical Center, and current research on bioprinting promises even more astonishing advances in treatment.

WellSpan Health Unites Expertise with Technology to Successfully Treat Structural Heart Conditions

Two years after adopting the WATCHMAN and MitraClip technologies, WellSpan York Hospital has become a high-volume center for structural heart procedures, fostering excellent outcomes and remarkable levels of patient satisfaction.

Groundbreaking CAR-T Cell Therapy Arrives at Penn State Cancer Institute

Penn State Cancer Institute is the first and only healthcare facility in central Pennsylvania to offer the leading-edge treatment CAR-T cell (CAR-T) therapy to adult patients with lymphoma who have exhausted all other options. Kite Pharma, a division of Gilead, chose just a handful of U.S. facilities for its rollout of the potentially lifesaving treatment, Yescarta, which uses gene editing to boost patients’ own T cells against their cancer.